Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progression of pancreatic cancer

Pancreatic cancer (PC) is the most severe and serious deadliest cancer type worldwide. Centromeric proteins (CENPs) family are involved in centromere formation and kinetochore organization during mitosis and play an important role in cancers. Here, we analyzed all CENPs in a panel of PC tissues and non-tumor tissues by genomics profile. We identified that CENPF is significantly upregulated in PC and correlated with poor prognosis of patients. Furthermore, silencing CENPF significantly inhibited PC cell proliferation, migration and epithelialmesenchymal transition (EMT), and caused cell cycle arrest at the G2/M phase, meanwhile, in vivo growth of pancreatic cells. Moreover, the TNF pathway and longevity regulating pathways are two potential pathways, which were regulated by CENPF. These findings investigated the clinical and functional contribution of CENPF as a novel biomarker for PC.

Automated summary

The study showed that CENPF is significantly upregulated in pancreatic cancer tissues and correlated with poor patient prognosis. Silencing CENPF inhibited cell proliferation and migration in pancreatic cancer cells, potentially through the regulation of the TNF pathway and longevity regulating pathways. These findings suggest that CENPF could serve as a novel biomarker for pancreatic cancer.